Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.
A little more than a month after Bay Area-based Freenome snagged $300 million in a Series D financing round, the company scored an additional $290 million from an investment made by Swiss pharma giant Roche.
Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.
Biopharma companies big and small presented exciting clinical studies at the European Society for Medical Oncology Congress 2021.
Oncology startup Volastra Therapeutics inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced the New York-based company’s seed funding round was extended from $12 million to $44 million.
Breast cancer overtook lung cancer as the most common form of the disease, accounting for nearly 12% of new cases each year worldwide, the World Health Organization said.
A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.
BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
